Skip Navigation


NDT Advance Access originally published online on April 17, 2009
Nephrology Dialysis Transplantation 2009 24(7):2018-2020; doi:10.1093/ndt/gfn713
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
24/7/2018    most recent
gfn713v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bahlmann, F. H.
Right arrow Articles by Fliser, D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bahlmann, F. H.
Right arrow Articles by Fliser, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


The plasticity of progenitor cells—why is it of interest to the nephrologists?

Ferdinand H. Bahlmann and Danilo Fliser

Department of Medicine IV, University of the Saarland, Homburg/Saar, Germany

Correspondence and offprint requests to: Ferdinand H. Bahlmann; E-mail: ferdinand.bahlmann@uniklinikum-saarland.de

Keywords: cardiovascular disease; chronic kidney disease; endothelial dysfunction; endothelial progenitor cells; regeneration

The first 150 words of the full text of this article appear below.

It is increasingly recognized that chronic kidney disease (CKD) goes in parallel with hypertension and several metabolic disorders such as dyslipidaemia, insulin resistance and hyperuricaemia [1]. These traditional as well as a variety of non-traditional cardiovascular risk factors contribute to accelerated vascular disease resulting into fatal clinical endpoints such as myocardial infarction, cerebro-vascular insults and/or ischaemic events of the lower limbs, which are the most important causes of morbidity and mortality in patients with CKD. In a meta-analysis related to CKD and cardiovascular disease in over 500 000 patients from all continents except Africa, the European Uraemic Toxin work (EUTox) group reported an increased risk of cardiovascular morbidity and mortality when the creatinine clearance falls below ~75 mL/min/1.73 m2 [2]. These findings underline the tremendous risk of patients to suffer from vascular disease even in the early stages of CKD. The search for novel therapeutic strategies to . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?